Rezolute/$RZLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rezolute
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Ticker
$RZLT
Sector
Primary listing
Employees
71
Headquarters
Website
Rezolute Metrics
BasicAdvanced
$818M
-
-$0.98
0.03
-
Price and volume
Market cap
$818M
Beta
0.03
52-week high
$9.72
52-week low
$2.22
Average daily volume
1.4M
Financial strength
Current ratio
14.367
Quick ratio
14.092
Long term debt to equity
0.606
Total debt to equity
0.996
Profitability
EBITDA (TTM)
-79.863
Management effectiveness
Return on assets (TTM)
-32.40%
Return on equity (TTM)
-52.56%
Valuation
Price to book
4.83
Price to tangible book (TTM)
4.83
Price to free cash flow (TTM)
-9.913
Free cash flow yield (TTM)
-10.09%
Free cash flow per share (TTM)
-0.909
Growth
Earnings per share change (TTM)
-26.33%
3-year earnings per share growth (CAGR)
-24.92%
10-year earnings per share growth (CAGR)
-28.25%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Bulls say / Bears say
Rezolute’s ersodetug received FDA Breakthrough Therapy Designation for the treatment of hypoglycemia caused by tumor hyperinsulinism, expediting its development and regulatory review pathway (Nasdaq).
Rezolute secured FDA alignment to streamline its Phase 3 upLIFT trial in tumor hyperinsulinism to an open-label study with as few as 16 participants, reducing trial duration and costs while leveraging sunRIZE data as confirmatory evidence (Nasdaq).
In April 2025, Rezolute closed an underwritten offering raising approximately $96.9 million in net proceeds, strengthening its balance sheet to support its clinical programs into mid-2027 (GlobeNewswire).
Rezolute reported a net loss of $18.9 million in the third quarter of fiscal 2025, reflecting high operating expenses and a substantial cash burn rate (Nasdaq).
The underwritten offering of 24.94 million shares at $3.25 per share represented significant dilution for existing shareholders, potentially weighing on the equity value (GlobeNewswire).
The pivotal Phase 3 sunRIZE trial’s topline results, not expected until December 2025, pose a major binary risk event where failure to meet primary endpoints could delay Rezolute’s regulatory progress (SEC filing).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Rezolute News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rezolute stock?
Rezolute (RZLT) has a market cap of $818M as of October 22, 2025.
What is the P/E ratio for Rezolute stock?
The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of October 22, 2025.
Does Rezolute stock pay dividends?
No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Rezolute dividend payment date?
Rezolute (RZLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rezolute?
Rezolute (RZLT) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.